Huons Signs 35 Billion KRW Export Contract for Dental Local Anesthetic with China

[Asia Economy Reporter Cho Hyun-ui] Huons Global announced on the 23rd that it has signed an export contract for the dental local anesthetic 'Lidocaine Epinephrine Injection' with the Chinese dental company Health-Miumiu.

The contract is worth approximately 35 billion KRW (30.44 million USD) over five years. Sales are expected to begin in the second quarter of 2022, after obtaining official local approval.

Lidocaine Epinephrine Injection provides a highly concentrated anesthetic effect on the required area. It is also a cartridge-type formulation that is safe from bacterial infection and can be used hygienically.

Once the exported Lidocaine Epinephrine Injection obtains local approval, it will become the first lidocaine combination product in China. Huons Global plans to actively expand its dental business in China starting from the second quarter of 2022 after completing local registration.

The company aims to capture more than 50% of the local market for local anesthetics containing epinephrine within five years. The local market for epinephrine-containing local anesthetics in China is approximately 51 billion KRW in size.

Yoon Sung-tae, Vice Chairman of Huons Global, said, "Huons' local anesthetics are exported to 20 countries worldwide, including the United States," and added, "We will lead the Chinese market by leveraging our excellent quality, the rarity of the cartridge formulation, and our partner's network."

This content was produced with the assistance of AI translation services.